Promoter holding
64.27%
LP
Link Pharmachem Limited - Due diligence report
A 360° intelligence report on Link Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Link Pharma — 360° Intelligence Report
Generated from MCA filings & public records68/100
Trust Score
Moderate
Link Pharma is assessed as Moderate with a Trust Score of 68/100. Link Pharma is an active public limited indian non-government company incorporated in 1984, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 10 Aug 2026 from the latest processed filings. Link Pharmachem Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
55/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
45/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
Charges position: 2 open (19.22 cr) · 15 satisfied (20.51 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bank Of India | 2 | 48.0 cr |
| State Bank Of India | 12 | 48.0 cr |
| Industrial Dev. Bank Of India | 1 | 48.0 cr |
| Small Industrial Dev. Bank Of India | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
Compliance Score: 55/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: DSE, EPFO, BSE.
- Litigation present in 1 court forum(s).
- Delayed payments to MSME suppliers disclosed (4 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| Sanjib Ranjit Dutta | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KHUSHBU PRAKASHBHAI PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RISHIKESH THAKUR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RACHNA MANAV GHAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RANGOLI SAURAV GADA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SURESH BALRAM DHATRAK | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SATISH GANPATRAO THAKUR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ROHIT JITENDRAPRASAD SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a majority stake - exact percentages are part of the full report.
Key managerial personnel: Sanjib Ranjit Dutta (CFO) · RISHIKESH THAKUR (Managing Director) · SATISH GANPATRAO THAKUR (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 75
Growth signals & trust indicators
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (55/100).
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.43 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence65/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment45/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 19.22 cr already registered.
- Compliance gaps should be priced into terms.
Investor view49/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events09 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
09 Aug 2024
Director appointed
RANGOLI SAURAV GADA (Director)
Director appointed
ROHIT JITENDRAPRASAD SHAH (Director)
03 Jun 2024
Charge satisfied
Others
01 Nov 2023
Director ceased
JAYESH PUSHPAVADAN JANI
19 Sep 2022
Director appointed
KHUSHBU PRAKASHBHAI PATEL (Company Secretary)
14 Sep 2020
Director appointed
RACHNA MANAV GHAI (Director)
24 Jun 2020
Director appointed
RISHIKESH THAKUR (Managing Director)
22 Jun 2020
Director ceased
BALVANT VINAYAKRAO RETAREKAR
15 Jun 2020
Director ceased
SAYALI SANJAY SOHONI
16 Jul 2016
Charge created
Others - 22.71 Lakh
23 Feb 2015
Director ceased
MILIND VASANT KELKAR
29 Sep 2011
Director ceased
DEVANG UTTAMCHAND SHAH
20 Apr 2009
Charge satisfied
State Bank Of India
10
Key Observations
Auto-generated from the data aboveRevenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Beryl Drugs | L02423MP1993PLC007840 | Indore, Madhya Pradesh, India |
| Nutribray Healthcare Private Limited | U24290HR2021PTC100232 | Gurgaon, Haryana, India |
| Alkali Metals | L27109TG1968PLC001196 | Hyderabad, Telangana, India |
| Crestchem | L24100GJ1991PLC015530 | Indrad, Gujarat, India |
| Akron Parentarals Private Limited | U24239AP1994PTC016773 | Muppalla, Andhra Pradesh, India |
| D P Petrochem Private Limited | U24290GJ2019PTC107895 | Limda, Gujarat, India |
| Saraf Organics Pvt Ltd | U24114MH1989PTC052696 | Mumbai, Maharashtra, India |
| India Gci Resitop | U24100TN2012FTC086663 | Thiruvallur, Tamil Nadu, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Link Pharma before audits and certifications: compliance score 55/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Link Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Link Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Link Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Link Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Link Pharma an active company?
Link Pharma has MCA status “Active” with a compliance score of 55/100 (Moderate).
Is Link Pharma financially healthy?
Link Pharma has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Link Pharma?
Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Link Pharma?
Promoters hold a majority stake - exact percentages are in the full report. 8 active director(s) are on record.
Does Link Pharma have loans or charges against its assets?
2 open charge(s) are registered against its assets, and 15 earlier charge(s) stand satisfied.
Is Link Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 55/100 (Moderate).
Is it risky to lend to Link Pharma?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
